Coherus BioSciences, Inc.
CHRS
$0.7818
-$0.0349-4.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 54.14M | 70.77M | 64.98M | 77.06M | 91.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.14M | 70.77M | 64.98M | 77.06M | 91.52M |
| Cost of Revenue | 33.86M | 20.74M | 28.37M | 34.59M | 84.57M |
| Gross Profit | 20.29M | 50.03M | 36.61M | 42.48M | 6.96M |
| SG&A Expenses | 34.60M | 34.74M | 35.17M | 45.93M | 47.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.69M | 77.16M | 85.49M | 108.99M | 154.93M |
| Operating Income | -35.55M | -6.39M | -20.51M | -31.93M | -63.41M |
| Income Before Tax | -50.70M | -10.75M | -12.92M | 102.88M | -79.65M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -50.70M | -10.75M | -12.92M | 102.88M | -79.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.70M | -10.75M | -12.92M | 102.88M | -79.65M |
| EBIT | -35.55M | -6.39M | -20.51M | -31.93M | -63.41M |
| EBITDA | -34.51M | -4.84M | -19.32M | -30.42M | -62.34M |
| EPS Basic | -0.44 | -0.09 | -0.11 | 0.91 | -0.71 |
| Normalized Basic EPS | -1.19 | -0.06 | 0.00 | -0.22 | -0.42 |
| EPS Diluted | -0.47 | -0.09 | -0.11 | 0.83 | -0.72 |
| Normalized Diluted EPS | -1.19 | -0.06 | 0.00 | -0.20 | -0.42 |
| Average Basic Shares Outstanding | 115.42M | 115.21M | 114.82M | 112.75M | 111.49M |
| Average Diluted Shares Outstanding | 115.42M | 115.21M | 114.82M | 125.53M | 111.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
